Sign up
Pharma Capital

Abzena moves UK operations to new Cambridge facility; signs lease for new San Diego base

The life sciences group is in the process of moving staff from its two current buildings to the new facility
scientist looking into a microscope
Abzena expects to have fully completed the move to the new UK facility by the end of January

Life sciences group Abzena plc (LON:ABZA) has moved into its new 30,000 square feet head office in Cambridge.

The AIM-quoted firm isn’t moving too far though; it is staying at the Babraham Research Campus where it previously ran its UK operations from two buildings.

Move to be fully completed this month

All of the operations – including head office functions and biology and chemistry research services – are currently being consolidated into the new, larger building. That process is expected to be completed by the end of this month (January).

The new facility has been purpose-built to suit the company’s needs and allows all of the UK-based science teams to work together in a single, state-of-the-art facility.

READ: Growth & investment strategy starting to bear fruit for Abzena PLC

Abzena has also entered into an agreement with Babraham Bioscience Technologies – the company which develops and manages the campus – to develop the antibody discovery services formerly provided by BBT’s technology development laboratory.

Lease signed for San Diego facility

Over in the US, Abzena has now signed a long-term lease for a new 50,000 square feet facility in San Diego which will bring all of its west coast biomanufacturing operations under one roof.

First to move into the new building will be the process and analytical development groups from the existing labs in Torrey Pines. They are expected to move in the second quarter of this year.

Further remodelling of the building will be required before the manufacturing division can relocate, but the facility should be fully operational early next year.

Abzena has hired Sartorius Stedim Biotech which will fit out the building with the necessary equipment, software and provide support for the design of the new biomanufacturing facility in San Diego.

READ: Abzena looks to a stronger second half after making sluggish start to financial year

Anzena is also in the process of building a GMP conjugation suite at its factory in Bristol, Pennsylvania which is on track to be ready by the end of the current quarter.

‘Important strategic step’

“The new facilities in Cambridge and San Diego are an important strategic step in the delivery of our integrated services model and will greatly enhance Abzena's operations,” said chief executive John Burt.

“The combination of state-of-the-art facilities and leading technologies will enable the group to support its international customers as they progress their drug development programmes from research into clinical trials.”

View full ABZA profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.